Get the Stockscreener App
0.8035
1.00%
-0.0081
After Hours:
.82
0.0165
+2.05%
Seres Therapeutics Inc stock is traded at $0.8035, with a volume of 906.99K.
It is down -1.00% in the last 24 hours and up +9.92% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$0.8116
Open:
$0.8116
24h Volume:
906.99K
Relative Volume:
0.39
Market Cap:
$137.19M
Revenue:
$126.33M
Net Income/Loss:
$-82.68M
P/E Ratio:
-1.3392
EPS:
-0.6
Net Cash Flow:
$-79.98M
1W Performance:
-3.51%
1M Performance:
+9.92%
6M Performance:
-8.09%
1Y Performance:
-23.48%
1-Day Range:
$0.7993
$0.83
1-Week Range:
$0.7993
$0.86
52-Week Range:
$0.54
$1.53
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
0.8035 | 137.19M | 126.33M | -82.68M | -79.98M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Purchased by Vontobel Holding Ltd. - MarketBeat
Seres Therapeutics executive sells shares worth $3,579 By Investing.com - Investing.com Nigeria
Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 Shares - MarketBeat
Seres Therapeutics exec Thomas Desrosier sells $3,485 in stock - Investing.com
Seres Therapeutics CEO Eric Shaff sells $10,314 in stock - Investing.com
Seres Therapeutics executive sells shares worth $3,579 - Investing.com
Seres Therapeutics EVP sells $2,704 in stock - Investing.com
Seres Therapeutics officer sells $3,203 in stock - Investing.com
Seres Therapeutics CEO Sells Shares - TradingView
Seres Therapeutics officer sells $3,203 in stock By Investing.com - Investing.com Canada
Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com - Defense World
Seres Therapeutics Inc (NASDAQ: MCRB) Stock Jumped 6.76% Over A Month – Is There Any Hope Of A Gain? - Marketing Sentinel
Janney Montgomery Scott LLC Lowers Stock Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Stock Performance Spotlight: Seres Therapeutics Inc (MCRB) Ends the Day at 0.78, Up by 0.13 - The Dwinnex
**Seres Therapeutics, Inc. Appoints Dr. Hans-Juergen Woerle as Class III Director** - Defense World
Seres Therapeutics Inc (MCRB) Stock: A Value Analysis - The News Heater
Seres Therapeutics expands board, appoints new director - Investing.com India
Check Out Seres Therapeutics Inc (MCRB)’s Trade Data Rather Than the Analysts’ Views - SETE News
Seres Therapeutics Expands Board with Nestlé’s Appointee - TipRanks
Recent Insider Activity Suggests Potential Gains for Seres Therapeutics Inc (MCRB) - Knox Daily
A year in review: Seres Therapeutics Inc (MCRB)’s performance in the last year - US Post News
5 Best Microbiome Companies (February 2025) - Securities.io
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageTime to Sell? - MarketBeat
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
**Seres Therapeutics, Inc. Posts Updated Corporate Presentation – 8-K Filing Review**** - Defense World
Seres Therapeutics receives $50 million from Nestlé Health Science By Investing.com - Investing.com Australia
Seres Therapeutics receives $50 million from Nestlé Health Science - MSN
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale - The Manila Times
Seres Therapeutics Receives $50M Payment from Nestlé, Extends Cash Runway to 2026 - StockTitan
Seres Therapeutics Strengthens Future with VOWST Sale - TipRanks
Seres Therapeutics Provides Corporate Updates and Financial Results - Defense World
Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World
StockNews.com Downgrades Seres Therapeutics (NASDAQ:MCRB) to Sell - MarketBeat
Seres announces new translational biomarker results from SER-155 Phase 1b study - Yahoo Finance
Geode Capital Management LLC Acquires 255,014 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates - The Manila Times
Seres Therapeutics Announces New Translational Biomarker - GlobeNewswire
Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows - StockTitan
State Street Corp Purchases 43,700 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.com - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageTime to Sell? - MarketBeat
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):